The monosaccharide L-Fucose is a key component of important glycan structures found on extracellular mucoproteins and glycoproteins, in breast milk, and in certain blood-group determinants. L-Fucose is essential for human development and health.
The importance of L-Fucose for health, and the effectiveness of L-Fucose as a therapeutic product, has been demonstrated impressively in the treatment of the rare disease leukocyte adhesion deficiency II (LAD II). The symptoms of LAD II include immunodeficiency due to the lack of selectin adhesion, as well as neutrophilia, intellectual disability, movement disorders and greatly reduced growth. It has been shown that this serious disease can be successfully treated by the oral administration of L-Fucose.
In the past, L-Fucose was obtained from marine algae. Jennewein Biotechnologie has successfully developed an environmentally friendly biotechnology-based production process that no longer requires the extraction of L-Fucose from algae and the resulting destruction of kelp forests. The L-Fucose produced by Jennewein Biotechnologie is a crystalline product with high purity.